Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTIC-R: Multiarm Therapeutic Study in Pre-ICU Patients With COVID-19 (Repurposed Drugs)
2020-001354-22Phase 4Unknown
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Apr 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in coronavirus disease 2019 (COVID-19) comparing Olumiant (baricitinib), Ultomiris (ravulizumab) and Standard of care control (3 arms). Primary endpoint: Time to composite endpoint of organ failure or death (up to Day 14). Status: unknown.
02
Drugs
baricitinibravulizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001354-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001354-22.